Microarray Assay for SARS-CoV-2 Clade Variant Genotyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting SARS-CoV-2, particularly Q-RT-PCR, have high false negative rates and are inadequate for early detection of weak symptomatic carriers and identifying clade variants, which are critical for pandemic management due to genetic variations and the complexity of COVID-19 diagnostics.
Innovation Solution
A method involving combined reverse transcription and asymmetric PCR amplification using fluorescently labeled primer pairs to generate amplicons, which are then hybridized to nucleic acid probes on a microarray for genotyping, allowing for the identification of SARS-CoV-2 clade variants by analyzing the relative signal intensity of wild type versus mutant probes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If Q-RT-PCR technology is used for SARS-CoV-2 detection, then the detection method is simple and widely available, but the false negative rate is high (15-30%) making it ineffective for early detection
Solution Approach 1:
The patent introduces an intermediary step of generating fluorescently labeled amplicons through asymmetric PCR amplification before hybridization to microarray probes. This intermediary amplification and labeling process enhances the sensitivity and reliability of detection, allowing detection of low viral loads that would produce false negatives in direct Q-RT-PCR testing.
Solution Approach 2:
The patent segments the detection process into distinct stages: RNA extraction, asymmetric PCR amplification with fluorescent labeling, and microarray hybridization. This segmentation allows each step to be optimized independently, with the amplification step specifically designed to enhance sensitivity for early detection while maintaining operational simplicity through standardized protocols.
2Productivity
If Q-RT-PCR is used for screening, then it can be deployed at population scale, but it cannot identify clade variants due to limited genotyping capability
Solution Approach 1:
The microarray platform is designed with universal probes that can detect conserved regions and variant-specific probes that detect clade-defining mutations. This multi-functional probe set allows the same assay to perform both population-scale screening and clade variant identification, making the system universally applicable for both purposes simultaneously.
Solution Approach 2:
The patent adds a new dimension of genetic variation analysis by incorporating multiple probe types (universal, variant-specific, and clade-specific) on the microarray. This dimensional expansion transforms the assay from simple presence/absence detection to comprehensive genotyping capability, enabling identification of clade variants while maintaining screening throughput.
3Measurement precision
If NGS is used for clade variant detection, then comprehensive genetic variation data is obtained, but the complexity of kit supply chain and personnel training makes it unsuitable for field-deployed public health screening
Solution Approach 1:
The patent extracts only the essential clade-defining genetic information by using targeted asymmetric PCR amplification followed by hybridization to specific probes. This extraction approach obtains the critical variant data needed for public health decision-making without requiring comprehensive whole-genome sequencing, thereby simplifying the supply chain and operational complexity while maintaining sufficient measurement precision for clade identification.
Solution Approach 2:
The microarray-based assay uses disposable microarray chips with pre-loaded probes, eliminating the need for expensive, complex NGS sequencing kits and infrastructure. This disposable chip approach reduces supply chain complexity and personnel training requirements while providing sufficient genetic variation detection capability for field-deployed screening.
4Measurement precision
If multiple TaqMan kits (10-15 kits per sample) are used for clade identification, then sequence content equivalent to Spike targeted NGS is generated, but the cost and logistics benefits of Q-RT-PCR are negated
Solution Approach 1:
The patent merges multiple detection functions into a single microarray chip that contains both universal probes for SARS-CoV-2 detection and multiple variant-specific probes for clade identification. This consolidation replaces the need for running multiple separate TaqMan kits, reducing the number of reagent kits required from 10-15 to one integrated microarray assay while maintaining comprehensive clade identification capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the sensitivity and specificity of SARS-CoV-2 detection and genotyping, enabling the identification of known variants and potentially unknown strains, thereby improving diagnostic accuracy and public health management.
Implementation Method 1
a combined reverse transcription and asymmetric PCR amplification reaction is performed on the total RNA using a plurality of fluorescently labeled primer pairs to generate a plurality of fluorescent labeled SARS-CoV-2 amplicons
Implementation Method 2
The plurality of fluorescently labeled SARS-CoV-2 amplicons are hybridized to a plurality of nucleic acid probes comprising universal probes, wild type probes and mutant probes, each having a sequence that specifically base-pairs with one of the target sequences in the fluorescently labeled SARS-CoV-2 amplicons
Data Source
AI summary
Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant and each clade variant is distinguished from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants. Also provided are methods for detecting and genotyping SARS-CoV-2.